Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2023-02-21 Annual Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZ 2022 Annual Report XBRL
Annual Report Classification · 100% confidence The document is explicitly titled 'AstraZeneca PLC Annual Report and Form 20-F Information 2022'. It contains comprehensive financial statements, management discussion and analysis, corporate governance reports, and strategic performance reviews for the full fiscal year 2022. It meets all the criteria for an Annual Report (10-K). FY 2022
2023-02-21 English
Annual Financial Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3305 characters) released via RNS (RNS Number : 5764Q) on February 21, 2023. The core content states that AstraZeneca PLC announced the 'publication of its Annual Report and Form 20-F Information 2022' and confirms that a copy will be submitted to the National Storage Mechanism and made available on the website. According to Rule 2, when a document is short and announces the publication of a major report (like the Annual Report, which would typically be a 10-K), it should be classified as a Report Publication Announcement (RPA). Although it mentions the Annual Report, the document itself is the announcement of that report's release, not the report itself.
2023-02-21 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a navigation page for the Swedish Financial Supervisory Authority (Finansinspektionen) portal for stock market information. It contains links for searching, reporting, and flagging, but does not contain any specific financial data, corporate reports, or regulatory announcements. As it is a general portal interface and does not fit into any specific category, it is classified as a general regulatory filing.
2023-02-21 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-02-21 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC as a report of a foreign issuer. The content focuses on a director's shareholding transaction, specifically the vesting of shares under the AstraZeneca Investment Plan to the CEO, Pascal Soriot. It details the number of shares acquired, the nature of the transaction, and related tax information. There is no financial performance data, earnings information, or management discussion. The document is primarily a notification of a personal share transaction by a company director. Therefore, it fits the category of Director's Dealing (DIRS). The document length is just over 5,000 characters, but the content clearly matches insider share transactions rather than a report or announcement of a report.
2023-02-13 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the vesting and acquisition of shares by the CFO. The content focuses on insider share transactions and compliance with EU Market Abuse Regulation. There are no financial statements, earnings data, or management discussion. The document is a regulatory filing reporting insider dealings, which fits the definition of Director's Dealing (DIRS). The document length is 7390 characters, sufficient to contain detailed transaction information. Therefore, the classification is DIRS with high confidence.
2023-02-13 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.